Shots:

• NMPA has approved HLX03 for the treatment of RA- AS and PsO. It is the first China-developed biosimilar- approved both in China and in the EU
• The approval marks the expansion of the Henlius’ commercial pipeline into the field of autoimmune diseases and the scope of patients befitted with the therapy
• Henlius will continue optimizing and upgrading the product- and cooperating with Wanbang Biopharma to promote the commercialization of biosimilar- to bring the high-quality treatment options to patients suffering from autoimmune diseases

 ­ Ref: Henlius | Image: Henlius